Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences

Leukemia

Volumn 22, Issue 1, 2008, Pages 124-131

  van Grotel, M ^a   Meijerink, J P P ^a   van Wering, E R ^b   Langerak, A W ^c   Beverloo, H B ^c   Buijs Gladdines, J G C A M ^a   Burger, N B ^a   Passier, M ^a   van Lieshout, E M ^a   Kamps, W A ^b,d   Veerman, A J P ^b,e   van Noesel, M M ^a   Pieters, R ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Dutch Childhood Oncology Group DCOG   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; CELL PROTEIN; HOMEODOMAIN PROTEIN; NOTCH1 RECEPTOR; PROTEIN AF10; PROTEIN CALM; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR HOX11; TRANSCRIPTION FACTOR HOX11L2; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE ARREST; CELL LINEAGE; CELL MATURATION; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC DISORDER; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPIC VARIATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA; TREND STUDY;

EID: 38349068493     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404957     Document Type: Article

References (48)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Thiel E, Kranz BR, Raghavachar A, Bartram CR, Loffler H, Messerer D et al. Prethymic phenotype and genotype of pre-T (CD7+/ER-)- cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989; 73: 1247-1258.
3. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematelogica 2005; 90: 1116-1127.
4. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993; 81: 2237-2251.
5. Rubnitz JE, Look AT. Molecular genetics of childhood leukemias. J Pediatr Hematol Oncol 1998; 20: 1-11.
6. Cauwelier B, Dastugue N, Cools J, Poppe B, Herens C, De Paepe A et al Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes. Leukemia 2006; 20: 1238-1244.
7. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007; 110: 1251-1261.
8. Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 2003; 102: 1000-1006.
9. Graux C, Cools I, Melotte C, Quentmeier H, Ferrando A, Levine R et al Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084-1089.
10. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007; 39: 593-595.
11. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
12. van Grotel M, Meijerink JP, Beverloo, HB, Langerak AW, Buys-Gladdines JG, Schneider P et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: A retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006; 91: 1212-1221.
13. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002; 100: 991-997.
14. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Results of EORTC studies 58881 and 58951. Blood 2004; 103: 442-450.
15. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003; 40: 274-280.
16. Gottardo NG, Jacoby PA, Sather HN, Reaman GH, Baker DL, Kees UR. Significance of HOX11L2/TLX3 expression in children with T-cell acute lymphoblastic leukemia treated on children's cancer group protocols. Leukemia 2005; 19: 1705-1708.
17. Mauvieux L, Leymarie V, Helias C, Perrusson N, Falkenrodt A, Lioure B et al. High incidence of Hox11L2 expression in children with T-ALL. Leukemia 2002; 16: 2417-2422.
18. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 2004; 363: 535-536.
19. Kees UR, Heerema NA, Kumar R, Watt PM, Baker DL, La MK et al. Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: A study from the Children's Cancer Group (CCG). Leukemia 2003; 17: 887-893.
20. Schneider NR, Carroll AJ, Shuster JJ, Pullen DJ, Link MP, Borowitz MJ et al. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: A pediatric oncology group report of 343 cases. Blood 2000; 96: 2543-2549.
21. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G et al Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151-1157.
22. Greaves MF. Differentiation-linked leukemogenesis in lymphocytes. Science 1986; 234: 697-704.
23. Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood 2004; 104: 4173-4180.
24. Breit TM, Mol EJ, Wolvers-Tettero IL, Ludwig WD, van Wering ER, van Dongen JJ. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med 1993; 177: 965-977.
25. Macintyre EA, Smit L, Ritz J, Kirsch IR, Strominger JL. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. Blood 1992; 80: 1511-1520.
26. Bene MC, Castoldi G. Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
27. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ et al. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A pediatric oncology group study. Blood 1988; 72: 1891-1897.
28. Ludwig WD, Harbott J, Bartram CR, Komischke B, Sperling C, Teichmann JV et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: Experience of the BFM study 86. Recent Results Cancer Res 1993; 131: 269-282.
29. Garand R, Voisin S, Papin S, Praloran V, Lenormand B, Favre M et al Characteristics of pro-T ALL subgroups: Comparison with late T-ALL. The Groupe d'Etude Immunologique des Leucemies. Leukemia 1993; 7: 161-167.
30. Vitale A, Guarini A. Ariola C, Mancini M, Mecucci C, Cuneo A et al Adult T-cell acute lymphoblastic leukemia: Biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006; 107: 473-479.
31. Asnafi V, Buzyn A. Thomas X, Huguet F, Vey N. Boiron JM et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: A LALA-94 study. Blood 2005; 105: 3072-3078.
32. Niehues T, Kapaun P, Harms DO, Burdach S, Kramm C, Korholz D et al A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia 1999; 13: 614-617.
33. Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343-362.
34. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
35. Kamps WA, Bokkerink JP, Hahlen K. Hermans J, Riehm H, Gadner H et al Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch childhood leukemia study group protocol ALL-7 (1988-1991). Blood 1999; 94: 1226-1236.
36. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16: 1099-1111.
37. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P et al. Differential mRNA expression'of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101: 1270-1276.
38. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001; 3: 55-61.
39. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusicn gene transcripts for residual disease detection in leukemia - a Europe against cancer program. Leukemia 2003; 17: 2318-2357.
40. Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers GJ, Van der Plas D et al. Translocation of BCR to chromosome 9: A new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer 1993; 8: 237-245.
41. van der Burg M, Poulsen TS, Hunger SP, Beverloo HB, Smit EM, Vang-Nielsen K et al. Split-signal FISH for detection of chromosome aberrations in 'acute lymphoblastic leukemia. Leukemia 2004; 18: 895-908.
42. van Wering ER, van der Linden-Schrever BE, Szczepanski T, Willemse MJ, Baars EA, van Wijngaarde-Schmitz HM et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: Implications for monitoring of minimal residual disease. Br J Haematol 2000; 110: 139-146.
43. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006; 108: 3520-3529.
44. Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Fox EA et al Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood 2004; 103 1909-1911.
45. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. SCL and LMO1 alter thymocyte differentiation: Inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol 2000; 1: 138-144.
46. Grutz GG, Bucher K, Lavenir I, Larson T, Larson R, Rabbitts TH. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J 1998; 17: 4594-4605.
47. Hsu HL, Wadman I, Baer R. Formation of in vivo complexes between the TAL1 and E2A polypeptides of leukemic T cells. Proc Natl Acad Sci USA 1994; 91: 3181-3185.
48. Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 1997; 16: 3145-3157.